Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $2.01, $0.41 better than the analyst estimate of $1.60. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.72 billion.

GUIDANCE:

Gilead Sciences sees FY2024 EPS of $3.60-$3.90, versus the consensus of $3.71. Gilead Sciences sees FY2024 revenue of $27.1-27.5 billion, versus the consensus of $27.583 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.